Malignant Peritoneum Mesothelioma with Hepatic Involvement: A Single Institution Experience in 5 Patients and Review of the Literature

Table 1

Clinical features and outcomes of the patients.

Case	Age	Sex	History of asbestos exposure	Clinical manifestation	Physical examination	Ascites	Positive immunohistochemical stains	Negative immunohistochemical stains	Treatment	Overall survival (months)
1	57	M	+	Abdominal distension	Abdominal tenderness	Massive ascites	Cal, MC, CK	CEA, HeP	Intraperitoneal cisplatin	5
2	69	F	+	Abdominal pain and distension	Abdominal tenderness	No ascites	Cal, MC, CK	CEA, HeP	Intraperitoneal cisplatin	6
3	51	F	+	Abdominal distension	Fullness in the flanks	Massive ascites	Cal, CK, EMA	CEA, HeP, MC	Intravenous and intraperitoneal cisplatin	7
4	45	F	+	Abdominal mass	A mass in the right abdomen	Massive ascites	Cal, EMA	CEA, HeP, MC, CK	Oophorectomy, omentectomy, and adjuvant chemotherapy	8
5	66	F	+	Abdominal distension	Abdominal tenderness	Massive ascites	Cal, MC, CK	CEA, HeP	Intravenous pemetrexed and cisplatin	/

Note: M: male; F: female; +: positive; Cal: calretinin; MC: mesothelin; CK: cytokeratin; HeP: hepatocyte; CEA: carcinoembryonic antigen; EMA: epithelial membrane antigen; /: alive up to now.